Log In
Print this Print this

Betanis, Betmiga, Myrbetriq, mirabegron (YM178)

  Manage Alerts
Collapse Summary General Information
Company Astellas Pharma Inc.
DescriptionAdrenergic receptor beta 3 (ADRB3) agonist extended-release tablets
Molecular Target Adrenergic receptor beta 3 (ADRB3)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationIncontinence
Indication DetailsTreat incontinence; Treat neurogenic detrusor overactivity and idiopathic overactive bladder in pediatric patients; Treat overactive bladder (OAB); Treat urinary frequency
Regulatory Designation


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today